ScreenerHero

NRIX Nurix Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · nurixtx.com
22.73USD+0.58%Mkt Cap: 2.36B $P/E: —

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.36B USD
Enterprise Value1.96B USD
Revenue (TTM)36.77M USD
Gross Profit-304.17M USD
Net Income (TTM)-264.46M USD
Revenue/Share0.37 USD
Last Price22.73 USD
Fiscal Year EndNov 2025
MR QuarterMay 2026
Employees317
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.21
PEG—
EV/EBITDA-5.55
EV/Revenue53.31
P/S63.79
P/B5.82
EPS (TTM)-3.41
EPS (Forward)-1.07
52W Range
8.21573% of range28.23
52W High28.23 USD
52W Low8.215 USD
Profitability
Gross Margin0.00%
Oper. Margin-1041.73%
EBITDA Margin0.00%
Profit Margin-314.90%
ROE-49.09%
ROA-38.43%
Growth
Revenue Growth-79.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-249.47M USD
CapEx (TTM)14.00M USD
FCF Margin-447.79%
FCF Yield-6.98%
Net Debt-385.39M USD
Net Debt/EBITDA1.09
Balance Sheet
Debt/Equity0.10
Current Ratio6.34
Quick Ratio6.18
Book Value/Sh3.88 USD
Cash/Share4.27 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)33.93 USD
Upside (mean)+49.3%
Target Range25.00 USD – 45.00 USD
25.00+49.3% to mean45.00
# Analysts14
Ownership
Shares Out.103.78M
Float74.11M
Insiders1.08%
Institutions114.88%
Short Interest
Short Ratio14.6d
Short % Float17.52%
Short % Out.17.32%
Shares Short17.98M
Short (prev mo.)17.98M
Technical
SMA 5025.28 (-10.1%)
SMA 20019.61 (+15.9%)
Beta1.82
S&P 52W Chg16.45%
Avg Vol (30d)1.33M
Avg Vol (10d)1.59M
Technical Indicators
RSI (14)35.4
MACD-0.6678
MACD Signal-0.4504
MACD Hist.-0.2173
BB Upper26.82 USD
BB Middle24.32 USD
BB Lower21.82 USD
BB Width20.56%
ATR (14)0.9626 USD
Vol Ratio (20d)1.11x